A study published in Molecular Psychiatry is the first to look at multiple levels of biology within women with postpartum depression (PPD) to see how women with the condition differ from those without it. PPD affects 1 in 7 women and has negative mental health consequences for both mother and child. However, the precise biological mechanisms behind the disorder are unknown.

“We don’t have PPD figured out,” said lead author Jerry Guintivano, Ph.D., assistant professor in the UNC Department of Psychiatry. “A lot of biological research focuses on candidate genes and hormones, and we do have a lead on some PPD-specific medications, but it’s important to take multiple avenues to target this condition. Not every manifestation of PPD is the same.”

That’s why Guintivano led a team of researchers from the UNC School of Medicine to conduct the largest transcriptome-wide association study for PPD to date. Previous studies have only analyzed whole blood samples. This study took a deeper look and examined the different components of blood. They took blood samples from 1,500 racially and ethnically diverse women from across North Carolina who had given birth within the past six weeks, 482 of whom were diagnosed with PPD. Researchers used RNA sequencing, DNA genotyping, and assessment of DNA methylation—amounting to three levels of basic biology evaluation—to look for differences in components of the blood samples from women with PPD versus women without PPD.

CMS officials disagree with the FDA’s reasoning, and are likely worried about the cost of covering a medication for hundreds of thousands of beneficiaries who might seek the treatment if it was broadly covered by Medicare. While CMS’s concern for taxpayers is understandable, it’s the FDA — not CMS — that has the statutory authority and deep medical expertise to assess a drug for approval. And Aduhelm passed the FDA’s assessment.

CMS arguably overstepped the bounds of its authority. Its decision is a huge blow to millions of Americans living with Alzheimer’s and their families. They are the losers in CMS’s decision, not only from the severe restriction on access to Aduhelm but also from its chilling effect on the development of other disease-modifying agents for people with Alzheimer’s. If CMS won’t pay for a treatment after the FDA legally approves it, why should a company bother pursuing this pathway?

CMS’s decision will affect the exploration for new treatments for Alzheimer’s for years, just at the time when new drugs appear to be making progress against this terrible disease.

Summary: Patients who suffer from frontotemporal dementia with extrapyramidal symptoms have brainstem atrophy and reduced metabolic activity in specific brain regions compared to those with FTD without extrapyramidal symptoms.

Source: University of Eastern Finland.

Frontotemporal dementia patients with extrapyramidal symptoms have brainstem atrophy and reduced metabolism in certain areas of the brain significantly more often than patients without extrapyramidal symptoms, a new study from the University of Eastern Finland shows. This observation can facilitate differential diagnostics in frontotemporal dementia.

A unprecedented global study of Alzheimer’s disease has uncovered an additional 42 genes that may affect a person’s risk of developing the disorder. Doctors hope to use that information to develop a more precise way to identify risk.